Exome Asset Management LLC Has $2.32 Million Position in Savara Inc. $SVRA

Key Points

• Exome Asset Management LLC increased its stake in Savara Inc. by 19.5%, owning 836,397 shares valued at approximately $2.3 million, making it the 24th largest holding in their investment portfolio.
• Several other institutional investors significantly increased their holdings in Savara in the fourth quarter, with D. E. Shaw & Co. Inc. raising its stake by 314.7%.
• Savara's recent quarterly earnings report missed analysts' expectations, revealing a loss of ($0.14) earnings per share compared to the anticipated ($0.12).

Exome Asset Management LLC boosted its holdings in Savara Inc. (NASDAQ:SVRA - Free Report) by 19.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 836,397 shares of the company's stock after buying an additional 136,699 shares during the quarter. Savara makes up approximately 2.0% of Exome Asset Management LLC's investment portfolio, making the stock its 24th largest position. Exome Asset Management LLC owned 0.48% of Savara worth $2,317,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD raised its holdings in Savara by 13.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 43,668 shares of the company's stock valued at $135,000 after buying an additional 5,236 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Savara by 3.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 143,661 shares of the company's stock valued at $441,000 after buying an additional 5,450 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in Savara by 25.3% in the 1st quarter. Farther Finance Advisors LLC now owns 32,314 shares of the company's stock valued at $92,000 after buying an additional 6,532 shares during the last quarter. Algert Global LLC raised its holdings in Savara by 7.3% in the 4th quarter. Algert Global LLC now owns 132,968 shares of the company's stock valued at $408,000 after buying an additional 9,000 shares during the last quarter. Finally, ProShare Advisors LLC raised its holdings in Savara by 28.8% in the 4th quarter. ProShare Advisors LLC now owns 40,627 shares of the company's stock valued at $125,000 after buying an additional 9,096 shares during the last quarter. Institutional investors own 87.93% of the company's stock.

Insider Transactions at Savara

In other Savara news, Director Richard J. Hawkins purchased 48,225 shares of Savara stock in a transaction that occurred on Friday, June 20th. The stock was acquired at an average price of $2.04 per share, with a total value of $98,379.00. Following the transaction, the director owned 115,466 shares in the company, valued at $235,550.64. This trade represents a 71.72% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.33% of the company's stock.

Savara Trading Down 6.3%

Shares of NASDAQ:SVRA traded down $0.24 during mid-day trading on Thursday, hitting $3.59. The company had a trading volume of 1,107,954 shares, compared to its average volume of 1,853,176. The firm has a fifty day moving average price of $2.85 and a 200 day moving average price of $2.74. The company has a market capitalization of $620.50 million, a PE ratio of -7.18 and a beta of 0.56. The company has a debt-to-equity ratio of 0.25, a current ratio of 11.08 and a quick ratio of 11.08. Savara Inc. has a one year low of $1.89 and a one year high of $4.70.

Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). As a group, research analysts forecast that Savara Inc. will post -0.45 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SVRA. HC Wainwright raised their price objective on shares of Savara from $5.00 to $8.00 and gave the company a "buy" rating in a report on Wednesday, September 3rd. Guggenheim raised their price target on shares of Savara from $8.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday. Oppenheimer raised their price target on shares of Savara from $6.00 to $8.00 and gave the stock an "outperform" rating in a report on Monday. Evercore ISI lowered their price target on shares of Savara from $3.00 to $2.00 and set an "in-line" rating for the company in a report on Wednesday, May 28th. Finally, Wells Fargo & Company lowered their price target on shares of Savara from $8.00 to $7.00 and set an "overweight" rating for the company in a report on Wednesday, May 28th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Savara has an average rating of "Moderate Buy" and a consensus target price of $7.50.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.